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Abstract:  Acquired  aplastic  anemia
hematopoietic bone marrow failure and peripheral cytopenia. The pathophysiology is immune 
mediated in most cases, activated T1 lymphocytes have been identified as effector cells . The 
disease can be successfully treated w
hematopoietic  stem  cell  transplantation.
syndrome of bone marrow failure following the development of acute seronegative hepatitis. 
HAA syndrome most often affects young males who presented severe pancytopenia two to 
three  months  after  an  episode  of  acute  hepatitis.  The  clinical  course  of  hepatitis  is  more 
frequently benign but a fulminant severe course is also described. The bone marrow failure 
can be explosive and severe and it is usually fatal if untreated, no correlations have been 
observed between severity of hepatitis and AA.
identified  and  most  cases  are  seronegative  for  known  hepatitis  viruses.  The  cli
characteristics  and response to immunotherapy indicate a central role for immune
mechanism in the pathogenesis of HAA. The initial target organ of the immune  response is 
the liver as suggested by the time interval between hepatitis and the
failure. Liver histology is characterized by T cell infiltrating the parenchyma as reported in 
acute  hepatitis.  Recently  in  HAA  it  has  been  demonstrated  intrahepatic    and  blood 
lymphocytes with  T  cell  repertoire similar  to  that of  con
expanded T cell clones return to a normal distribution after response to immunosuppressive 
treatment, suggesting the antigen or T cell clearance. Therapeutic options are the same as 
acquired aplastic anemia.
Thalassemia:  Aplastic  anemia  (AA)  the  most 
common bone marrow failure syndrome, is defined 
as  peripheral  blood  cytopenia  and  a  hypocellular 
bone marrow.
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Acquired  aplastic  anemia (aAA)  is  a  severe  and  rare  disease,  characterized  by 
hematopoietic bone marrow failure and peripheral cytopenia. The pathophysiology is immune 
mediated in most cases, activated T1 lymphocytes have been identified as effector cells . The 
disease can be successfully treated with combined immunosuppressive therapy or allogeneic 
hematopoietic  stem  cell  transplantation. Hepatitis-associated  aplastic  anemia  (HAA)  is  a 
syndrome of bone marrow failure following the development of acute seronegative hepatitis. 
affects young males who presented severe pancytopenia two to 
three  months  after  an  episode  of  acute  hepatitis.  The  clinical  course  of  hepatitis  is  more 
frequently benign but a fulminant severe course is also described. The bone marrow failure 
sive and severe and it is usually fatal if untreated, no correlations have been 
observed between severity of hepatitis and AA. In none of the  studies a specific virus could be 
identified  and  most  cases  are  seronegative  for  known  hepatitis  viruses.  The  cli
characteristics  and response to immunotherapy indicate a central role for immune
mechanism in the pathogenesis of HAA. The initial target organ of the immune  response is 
the liver as suggested by the time interval between hepatitis and the onset of bone marrow 
Liver histology is characterized by T cell infiltrating the parenchyma as reported in 
acute  hepatitis.  Recently  in  HAA  it  has  been  demonstrated  intrahepatic    and  blood 
lymphocytes with  T  cell  repertoire similar  to  that of  confirmed viral  acute hepatitis.  The 
expanded T cell clones return to a normal distribution after response to immunosuppressive 
treatment, suggesting the antigen or T cell clearance. Therapeutic options are the same as 
Aplastic  anemia  (AA)  the  most 
common bone marrow failure syndrome, is defined 
as  peripheral  blood  cytopenia  and  a  hypocellular 
AA  may  develop  as  primary  hemat
disorder, most often idiopatic, or result from some 
causal factors as chemical toxins, drugs, viruses.
The  diagnosis  of  AA  needs  an  accurate 
differential  diagnosis  to  exclude  other  causes  of 
pancytopenia  such  as  primary  marrow  diseases 
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and  rare  disease,  characterized  by 
hematopoietic bone marrow failure and peripheral cytopenia. The pathophysiology is immune 
mediated in most cases, activated T1 lymphocytes have been identified as effector cells . The 
ith combined immunosuppressive therapy or allogeneic 
associated  aplastic  anemia  (HAA)  is  a 
syndrome of bone marrow failure following the development of acute seronegative hepatitis. 
affects young males who presented severe pancytopenia two to 
three  months  after  an  episode  of  acute  hepatitis.  The  clinical  course  of  hepatitis  is  more 
frequently benign but a fulminant severe course is also described. The bone marrow failure 
sive and severe and it is usually fatal if untreated, no correlations have been 
In none of the  studies a specific virus could be 
identified  and  most  cases  are  seronegative  for  known  hepatitis  viruses.  The  clinical 
characteristics  and response to immunotherapy indicate a central role for immune-mediated 
mechanism in the pathogenesis of HAA. The initial target organ of the immune  response is 
onset of bone marrow 
Liver histology is characterized by T cell infiltrating the parenchyma as reported in 
acute  hepatitis.  Recently  in  HAA  it  has  been  demonstrated  intrahepatic    and  blood 
firmed viral  acute hepatitis.  The 
expanded T cell clones return to a normal distribution after response to immunosuppressive 
treatment, suggesting the antigen or T cell clearance. Therapeutic options are the same as 
AA  may  develop  as  primary  hematological 
disorder, most often idiopatic, or result from some 
causal factors as chemical toxins, drugs, viruses.
The  diagnosis  of  AA  needs  an  accurate 
differential  diagnosis  to  exclude  other  causes  of 
pancytopenia  such  as  primary  marrow  diseases Medit J Hemat Infect Dis 2009; 1(3); Open Journal System 
(myelodisplastic  syndromes,  acute  leukaemia, 
lymphomas  of  the  marrow)  or  non  hematologic 
diseases (LES, sarcoidosis, deficit  of folate or B12, 
alcohol abuse, hypotiroidism).
Bone  marrow  functions  are  usually  depressed 
uniformly  resulting  in  anemia,  leucopenia  and 
thrombocytopenia  in  peripheral  blood,  but  less 
severe type of marrow failure are characterized by 
monocytopenia  or  bicytopenias  or  by  moderate 
degrees of cytopenia. 
The disease is infrequent, the epidemiology and 
incidence rate of acquired AA  reported in two large 
controlled  studies  are  2/million  in  the  West  and
about 2-3 fold higher in Asia
1,2. This difference in 
geographic incidence does not have a sactisfatory 
explanation,  probably  results  mainly  from 
environmental causes rather than  genetic factors
3. 
The classification of AA relies on pathophysiologic 
pathways that identify two main forms:  acquired 
and congenital AA. The majority  of the acquired 
forms are idiopathic and  no causative factors might 
be identified (Table 1).
Pathophysiology:  Acquired  Aplastic  Anemia  
(aAA) has been associated with several factors that 
are  responsible  of  qualitative  and  quantitative 
defects  of hematopoietic  stem cells, abnormalities 
of marrow stroma or defects of cell maturation and 
differentiation.  The  use  of  chemicals  and  drugs, 
some  viral  infections  and  autoimmune  diseases 
have been identified as causal factors in etiology of 
aAA.  The  relationship  with  benzene, 
petrochemicals and insecticides is rarely described 
but well known
4,5.  Drugs are implicated in about 
25%  of  aAA  and  can  be  divided  into  two  major 
classes:  cytotoxic  drugs  used  in  cancer 
chemotherapy with a known  dose-dependent effect 
and  medical  drugs  used  in  community  with  an 
unexpected  idiosyncratic  effect
6,7. 
Overrepresentation  of  deletions  in  the  drug-
metabolizing glutathione-S-transferase genes might 
increase  toxic  drug  intermediate  products  as 
observed  in  some  series
8.  No  defined  mechanism 
has been identified  for chloramphenicol, the most 
famous between charged agents
9. The mechanisms 
that  induce  development  of  aAA  after  drug 
exposure  include  direct  toxic  effect  and  immune 
mediate  destruction.  The  low  probability  of 
developing  aAA  after  a  drug  therapy  might  arise 
from  the  infrequent  association  with  enzymatic 
defective  pathways,  genetic  variations  of 
methabolism  and host susceptibility to the action of 
toxic  compound.  Drug-induced  aplasia  does  not 
have  specific  clinical  features  thus  cannot  be 
distinguished from idiopatic form of the disease: the 
clinical  course,  the  favourable  response  to 
immunosuppressive therapy and the survival are the 
same as in idiopathic aAA.
Viral infections are associated with some forms 
of hematopoietic suppression, typically neutropenia 
or  less  frequently  thrombocytopenia.  Damage  of 
hematopoietic  bone  marrow  may  be  induced  by 
direct  lysis  of stem cells  or  by immune-mediated 
destruction.  Infectious  mononucleosis  due  to 
Epstein-Barr virus (EBV) is commonly associated 
with  some  degrees  of  myelosuppression,  more 
frequently  neutropenia  or  thrombocytopenia, 
whereas  it  is  only rarely  complicated  by  AA. 
Pancytopenia  can  occur  either  during  the  acute 
phase  or  shortly  after  symptoms  disappearance. 
Patients  recovered  spontaneously  or  after 
immunosuppressive  therapy,  hematopoietic 
recovery  after  antiviral  treatments  are  also 
observed
10.  Parvovirus  B19  infects  pro-
erythroblasts and leads to erythroid aplasia, but may 
also be associated with bone marrow failure 
11. HIV 
infection  is  frequently  associated  with  variable 
degrees of cytopenia.
In the last decades an unified immune-mediated 
mechanism  with  active  destruction  of  
hematopoietic  stem  cells  by  T  lymphocytes  has 
been proposed in most forms of aAA, the clinical 
and pathophysiologic observations have supported 
this hypothesis. The aberrant immune response may 
be triggered by drugs, virus, chemical exposure or, 
as in the majority of the cases, without evidence of  
etiologic factor
12. 
aAA  shares  some  features  with  other 
autoimmune disorders that are characterized by T-
cell  mediated  tissue-specific    distruction.  The 
cascade of events: cytotoxic lymphocyte activation, 
cytokine  production  and  specific  target  organ 
elimination    are  common  to  all  autoimmune 
disorders.  Further   the  successful  response  of the 
majority  of  AA  to  immunosuppressive  treatment 
remains  the  best  evidence  of  immune 
pathophysiology.
The  effector  cells  were  identified  by 
immunophenotyping  as  activated  T  cells, 
expressing  Th1  cytokines,  expecially  gamma-
interferon (INF- and tumor necrosis factor alpha 
(TNF- .  Type  1  cytokines  induce  apoptosis  in 
CD34  target  cells,    throught  the  FAS-dependent 
pathways of cell death
13, 14, 15.
The  reasons  why  T  cells  are  activated    in 
aplastic  anemia  is  still  unclear,  several  possible 
mechanisms are involved. Medit J Hemat Infect Dis 2009; 1(3); Open Journal System 
Table 1. Classification of aplastic anemia.
Acquired
Idiopatic
Secondary Irradiation
Drugs  and  chemical:  cytotoxic  agents,  benzene,  chloramphenicol,  gold  salts, 
nonsteroidal anti-inflammatory drugs
Idiosyncratic reactions
Viruses: Epstein-Barr virus, hepatitis virus unidentified, Parvovirus B19, HIV
Immune diseases
Pregnancy
Paroxysmal nocturnal hemoglobinuria
Inherited aplastic anemia Fanconi’s anemia
Dyskeratosis congenital
Amegakaryocytic thrombocytopenia
Shwachman-Diamond syndrome
HLA-DR2 is overrepresented in some patients, 
suggesting    a  role  for  antigen  recognition,  it  is 
associated with a better response to cyclosporine
16. 
Polymorphisms  in  cytokine  genes  of    tumor 
necrosis factor-, interferon gamma and interleukin 
6 , related with an increased immune response, have
also been observed
17,18.
Another  evidence  of  immune-mediated 
pathogenesis  comes  from  a  study  showing  that 
regulatory T cells (Tregs) are decreased in acquired 
aplastic  anemia  as  well  as  in  other  auto  immune 
diseases.  Tregs  control  the  development  and 
progression  of  autoimmunity  by  suppressing 
autoreactive T cells
19. A Tregs  defect could explain 
the increased activated autoreactive T cells. 
T-bet is a member of T-box family trascription 
factors  and is  responsible  for  the  shift  of CD4 T 
cells into the Th1 phenotype. T-bet is up-regulated 
in  T  lymphocytes  from aAA patients  and  bounds 
directely to the proximal site of the INF-promoter, 
without  any  prior  stimulation,  inducing  an  active 
trascription of INF-gene
20.  Mutations in PRF1, 
the perforin gene, and mutations in SAP, encoding 
for  small  modulator  protein  that  inhibits  INF-
production,  are  described  in  inherited  and 
acquired aplastic anemia
21. 
The  immune  attack  induces  marrow  failure 
secondary  to  reduced  number  and  function  of 
hematopoietic stem cells. 
Stem-cell assays in vitro as evaluation of LTC-
IC  or  cobblestone  forming-cells  are  negatively 
affected,  showing  slow  or  absent  colony 
formation
22. Microarray of CD34+ cells from bone 
marrow of AA patients identified a trascriptome in 
which  genes  involved  in  apoptosis  were  up-
regulated.  A  similar  trascriptional  pattern  was 
observed in normal CD34+ cells after exposure to 
INF-

peculiar characteristic of white blood cells in 
AA is short telomeres
24. Telomere shortening may 
be secondary to hematopoietic stem cell replication 
and  exhaustion,  but  other  possible  reasons  of 
shortening have been  suggested.  In some patients 
with  inherited  bone  marrow  failure  syndrome  a 
genetic  basis  was  also  indicated  for  telomere 
deficiency. Mutations in genes that repair or protect 
telomeres are probably implicated in some forms of 
AA, but have been observed in only 10% of cases, 
whereas telomeres are short in about half of patients 
with  aplastic  anemia
25.  Other  alternative 
mechanisms of repair not yet identified are probably 
involved in some cases. 
A  complication  of  aAA  is  cell  clonal 
proliferation  that  coexists  or  appears  as  a  late 
sequelae and its possible evolution to hematologic 
diseases such as myelodisplasia or acute leukemia. 
At diagnosis fifty percent of patients with aAA have 
expanded  population  of  paroxysmal  nocturnal 
hemoglobinuria    (PNH)  cells,  detected  by  flow 
cytometry, and is a predictive marker of favourable 
response  to  immunosuppressive  therapy 
26.  In the 
majority  of  cases  PHN  clones  are  small  and  no 
clinical manifestations are present.
Clonal  caryotypic  evolutions  are  observed  at 
constant rate after  diagnosis.  The   overall risk of 
developing a clonal cytogenetyc abnormality at 10 
years is  between 5% and 20% the most common 
cytogenetic  abnormalities  are  aberration of 
chromosome 7 and trisomy 8
27. 
Clinical Features: Symptoms occurring in aplastic 
anemia  result  from  the  peripheral  cytopenia  and, 
except for those due to low blood cell count, the 
majority  of  patients  did  not  have  specific 
symptoms. 
The  findings  on  physical examination  usually 
reflect  the  severity  of    pancytopenia.  All  of  the 
blood cells may be depressed or a single cytopenia 
may be more clinically evident. Skin and mucosal 
bleedings  at  various  severity  degrees  related  to Medit J Hemat Infect Dis 2009; 1(3); Open Journal System 
thrombocytopenia  are  the  most  common  clinical 
manifestations. Anemia symptoms may be present, 
but low levels of hemoglobin can be tolerated very 
well  without  any  patient’s  complaints  because  of 
adaptation  to  a  gradual  reduction  of  hemoglobin. 
Granulocytopenia may  induce  infection, but  fever 
and  infections  are  uncommon  at  diagnosis,  the 
typical sore throat of agranulocytosis  is not  often 
observed,  probably  because  other  alarming 
symptoms seek medical observation.
Acquired  aplastic  anemia  is  a  diagnosis  of 
exclusion.  Clinical  history  and  physical 
examination  should  be  carefully  conducted  to 
exclude  other  conditions  associated  with 
pancytopenia or a secondary cytopenia. Congenital 
marrow failure such as Fanconi anemia (FA) can be 
suspected in children or teenager with bone marrow 
failure and some characteristic physical anomalies, 
the  most  common  is  skin  hyperpigmentation  and 
café au lait spots. The majority of patients are small 
and  have  short    stature,  malformations  involving 
face  and  the  upper  limbs  are  frequent.  FA  is  a
chromosome instability syndrome characterized by 
hypersensitivity  to  interstrand  DNA    crosslinking 
agents as di-epoxibutane (DEB) and mitomycin C. 
Chromosomal  breakage  test  with  DEB  show  an 
excessive  chromosomal  breakage  in  peripheral 
blood lymphocytes from FA patients.
Laboratory  screening  and  data  are  also 
irreplaceable  tools  to  identify  other  cause  of 
cytopenia and more to grade the severity of aplastic 
anemia as defined by peripheral blood cell counts. 
(Table 2) 
Examination of the bone marrow is basic for the 
diagnosis  of  AA,  the  marrow  must  be  assessed 
quantitatively  and  qualitatively  for  cellularity  and 
morpholology of hematopoietic cells.
Marrow  aspiration  smear  and  bone  marrow 
biopsy  specimen  should  be  performed  always,  an 
adeguate sample is required for the diagnosis and 
sometime it  may be necessary to repeat a second 
procedure.  Marrow  examination  should  include 
flow-cytometry for phenotypic analysis to exclude 
acute leukemia and myelodisplasia and evaluation 
of  glycophosphoinositol-anchored  proteins  to 
diagnose  PNH.  Bone  marrow  cytogenetics  is 
diagnostically important, kariotype of marrow cells 
is  usually  normal  in  AA,  but  frequently  a  clonal 
abnormality  is  observed  in  myelodisplastic 
syndromes.
Treatment  of  Acquired  Aplastic  Anemia:  The 
therapeutic  choice  is  based  on  aplastic  anemia 
severity,  thus  on  peripheral  blood  cell  count. 
Patients  with  moderate  cytopenia  not  requiring 
regular transfusions can  receive  supportive therapy 
with  low  dose  steroid,  or  cyclosporine  in 
combination with ATG , but few controlled studies 
have addressed moderate aAA
28.  Androgen may be 
effective  in  presence  of  residual  hematopoietic 
function. In vitro androgens increase the telomerase 
activity in human lymphocytes and CD34 cells,  this 
action    probably  supports the  recovery  of 
hematopoiesis
29.
Table 2. Grading of Aplastic Anemia
Severe aplastic anemia
Bone marrow cellularity <30%
Two of  three peripheral blood criteria:
-absolute neutrophil count
-platelet count
-reticulocyte count
500- 200 /mm3
<20.000/mm3
<40.000/mm3
VERY SEVERE APLASTIC ANEMIA
-absolute neutrophil count <200/mm3
MODERATE APLASTIC ANEMIA
Patients with pancytopenia who do not 
fitfull the criteria of severe disease
Patients  with  severe  aplastic  anemia can  be 
offered  combined  immunosuppressive  treatment 
(IST)  or  hematopoietic  stem  cell  transplantation 
(HSCT) .
Antitymocyte globulin (ATG) and cyclosporine 
(CSA)  is  the  most  common  immunosuppressive 
regimen,  based  on  the  outcome  of  large 
studies
11,30,31. Both horse and rabbit ATG have been 
used,  ATG  are  produced  by  immunizing  animals 
(rabbit or horse) against human thymocyte and its 
activity  relies  on  immunomodulation  and 
lymphotoxicity  associated  to  a  preferential 
depletion of activated T cells. The larger experience 
is with ATG produced in horse, although both horse 
and rabbit ATG have been used successfully.
Frickhofen  et  al.
32,  comparing  treatment  with 
ATG  plus  CSA  versus  ATG  alone  in  long  term 
follow  up,  showed  a  difference  in  event  free 
survival,  indicating  a  higher  rate  of  relapse  in 
patients  given  ATG  alone  requiring  additional  IT 
course; however at 10 years survival  no difference 
was observed 
Time  of  response  to  therapy  with  ATG  plus 
CSA is 120 days as median, where response can be 
defined  as  complete  (CR)  and  partial  (PR):  CR  
relies  on  normal  peripheral  blood  count,  PR 
requires a transfusion independence. Medit J Hemat Infect Dis 2009; 1(3); Open Journal System 
Global response rates  (CR plus PR) are about 
60%  as reported  from  several  studies
32,33,34. In  a 
study
30 from  the  EBMT  Severe  Aplastic  Anemia 
Working  Party  on  almost  1000  patients  the  most 
important  negative  prognostic  factors  on  survival 
was  age  (older  than  16  years)  and  interval  time 
between  diagnosis  and    therapy  over  23  days. 
Neutrophil  count,  in  contrast  with  a  previous 
study
35,  had  no  influence  on  survival.  Relapse  is 
defined as renewed need for transfusion in patient 
who  achieved  previous  transfusion  independence 
for at least 3 months and occurring in about 30% of 
patients. Relapse can be successfully treated with a 
second course of IST
36,37.
In  large randomized studies the addition of G-
CSF improved neutrophil count,  but not  survival at 
3  years
38,39;  furthermore  two  retrospective  studies 
show an increased risk of late clonal disorders in 
patients  receiving  G-CSF
40,41 Data  from  a  recent 
meta-analysis  confirms  that  hematopoietic  growth 
factors are not recommend in aAA
42.
Allogeneic  Hematopoietic  Stem  Cell 
Transplantation (HSCT) replaces hematopoietic and 
immune  system  curing  the  majority  of  patients. 
Standard  conditioning  consisted  of 
cyclophosphamide  200mg/m
2 with  ATG,  this 
preparative  regimen  does  not  cause  infertility  or 
second  tumours  and  offers  an  excellent  response 
rate
30.  An  IBMTR  study  showed  77%  5-years 
survival in matched sibling donor transplantation, in 
children  and patients allograft  who are minimally 
transfused improved results have been observed and 
survival ranged from 80% to 90%
43.
A report from EBMT analyzed more than 1500 
patients  receiving  allogeneic  transplantation. 
Favorable  prognostic  factors  on  survival  were: 
years  of  transplantation  after  1997,  a  matched 
sibling  donor,  an  age  younger  than  16  years,  an 
interval  between  diagnosis  and  transplant  of  less 
than  83 days and a conditioning regimen without 
radiation. The survival for patients younger than 16 
years is 91%, but for older patients the results are 
less encouraging with survival of 51% in patients 
aged over 40 years 
30.
A matched sibling donor is available in about 
30% of cases. The outcome is poor in patients who 
have  failed  IS,  thus  in  such  patients  a  transplant
from matched unrelated donor (MUD) is a suitable 
treatment. Data from the European Registry show a 
rejection rate of 15%, an incidence of  acute GVHD 
of 48% and  survival at 5 years estimated at 39%  in 
HSCT from MUD performed from 1988 to 1998
44. 
Significant progress has been made in recent years 
addressing  the  issue  of  conditioning  regimen,  but 
also the degree of class I HLA match and the time  
interval  from  diagnosis  are  important.  A 
retrospective  analysis  from  the  Japanese  Registry 
suggested  that  in  patients  with  most  favourable 
characteristic  and  conditioned  with  low  dose 
radiation  survival is comparable with HSCT from 
matched sibling donors
45.
Bacigalupo  et  al.  for  the  EBMT  Aplastic 
Anemia  Working  Party  obtained  encouraging 
results  employing    a  non-radiation-based 
conditioning with 70% of survivors, although reject  
was high in adults older than 14 years
46.
In  conclusion  the  treatment  of  AA  has 
improved  dramatically  over  the  last  years  and  a 
long  term  survival  of  more  than  75  %  can  be 
achieved with either IST or HSCT.
Hepatitis-Associated Aplastic Anemia: Hepatitis-
associated  aplastic  anemia  (HAA)  is  a  variant  of 
aplastic anemia  in which aplastic anemia follows 
an acute seronegative  hepatitis. This syndrome was 
first  described  in  two  patients  in  1955  and  from 
1975  more  than  200  cases  have been 
documented
47,48.
HAA  is  not  uncommon,  with  an  episode  of 
hepatitis preceding the onset of bone marrow failure 
in 2% to 5% of cases of AA in Europe and United 
States
49,  the  incidence  is  higher  in  Asia  ranging 
from   4  to  10%,  where  it  is  associated  with  low 
socioeconomic status, rice farming and agricultural 
pesticides exposure
50.
Development of AA is also described following 
orthotopic  liver  transplant  (LTx)  for  viral 
seronegative  hepatitis.  In  a  multicentric  review 
study of 32 patients undergoing LTx for acute non-
A non-B hepatitis nine (28%) developed AA 
51.  In 
another study aplastic anemia developed  in 33 % (6 
of 18) of children who required liver transplantation 
for  fulminant  hepatitis
52.  This  high  incidence 
contrasts with the low incidence of AA, less than 
1%,  reported  after  LTx  for  other  causes  and 
strongly  suggests  that  the  etiologic  agent  of 
hepatitis  is  probably  involved  also  in  the  
pathogenesis of AA  after transplant.
HAA  syndrome  has  some  typical  clinical 
features:  most  often  affects  young  males  who 
presented severe pancytopenia two to three months 
after  an  episode  of  acute  hepatitis.  Hepatitis  
presents variability in clinical features but generally 
follows  a  benign  course,  showing  a  partial  or 
complete  resolution  before  AA  onset.  The  bone 
marrow failure can be explosive and severe and it is 
usually fatal if untreated, no correlations have been 
observed between severity of hepatitis and AA.Medit J Hemat Infect Dis 2009; 1(3); Open Journal System 
The hepatitis  was clinically indistin-guishable 
from  a  typical  viral  hepatitis,  but  in  no  study  a 
specific  virus  was  identified  and  most  cases  are 
seronegative for known hepatitis viruses, including 
A,  B,  C  and  G  virus.  HGV  and  TTV  have been 
suspected  as  agents  of  hepatitis  but  no  study 
confirms  this  relationship
53,54.  SEN  virus  is  a 
circovirus  with  eight  different  variants,  SENV-D 
and  SENV-H  were  found  in  more  than  50%  of 
transfusion-associated    hepatitis,  but  the  etiologic 
role in liver damage is not clear. In patients with 
HAA SEN viruses D and H were detected by PCR  
amplification,  but  patients  probably  acquired  the 
virus  from  transfusions,  thus  the  relationship 
between  SENV  and  HAA  remains  to  be 
established
55.
The current treatments of HAA are supportive 
therapy, IST and allogeneic HSCT, as in the setting 
of others forms of AA.
A retrospective analysis of ten cases of HAA 
referred  by  the  Clinical  Center  at  the  National 
Institutes of Health (NIH) did not show evidence of 
active hepatitis in the sera of patient by serologic or 
PCR  evaluations.  All  patients  had  evidence  of 
severe  AA  and  presented  elevated  liver  enzyme 
levels. They were treated with immunosuppressive 
treatment which consisted of a four-day course of 
intravenous  antithymocyte  globulin  and  oral 
cyclosporine  for  6  months,  seven  patients 
responded. Liver enzyme returned to normal range 
within  one  month  after  therapy,  hematologic 
recovery  was  slower,  occurring  after  at  least  six 
months.  At  the  presentation all  patients  had 
activated  CD8  lymphocytes  in  peripheral  blood, 
after  immunosuppressive  treatment  CD8  cells 
decreased  in  all  patients  but  one  who  did  not 
respond,  suggesting  that  liver  and  bone  marrow 
associated damages are immune-mediated
54.
Osugi et al. evaluated the efficacy of ATG and 
CSA in 44 children with HAA. Response rate at 6 
months  was  70%,  no  hepatic  toxicity  related  to 
therapy was observed and a rapid decrease in ALT 
levels were reported
56.
Another  study  assessed  the  efficacy  of 
allogeneic bone marrow transplantation in patients 
with HAA
53. None had evidence of hepatitis virus 
A,  B,  C,  E,  and  G  at  the  time  of  diagnosis. 
Seventeen  patients  underwent  BMT  from  HLA-
matched donors, twelve were alive at mean follow 
up  of  38  months;  survival  and  transplant  related 
mortality were similar to those patients transplanted 
for  idiopathic AA, no cases  of recurrent hepatitis 
occurred during the follow- up period. 
A report from EBMT Severe Aplastic Anemia 
Working  Party  showed  that  previous  hepatic 
damage  from  viral  hepatitis  and  liver  functions 
abnormalities  did  not  appear  to  increase  the 
toxicities  from  hepatocellular  damage in  the  post 
transplant course
57. 
The  clinical  characteristics  and  response  to 
immunotherapy indicate a central role for immune-
mediated mechanism in the pathogenesis of HAA. 
The initial target organ of the immune response is 
the liver as suggested by the time interval between 
hepatitis and the onset of bone marrow failure.
In acute B and C hepatitis and in autoimmune 
hepatitis liver histology is characterized by T cell 
infiltrating  the  parenchyma.  Analysis  of  T  cell 
repertoire  in  these  cases  has  demonstrated 
clonotypic expansions in T Cell Receptor (TCR) V
subfamilies,  indicating  a high  restriction in  the  T 
cell  composition  of  lymphocytes  infiltrating  the 
liver
58.
Lu  investigated  the  T  cell  repertoire  of 
intrahepatic  lymphocytes  on  HAA  patients  and 
reported that there is an infiltration of both clonal 
and many non clonal T cells with a T-cell repertoire 
similar  to  that  of  both  viral  B  and  C and 
autoimmune-hepatitis
59. The expanded T cell clones 
return  to  a  normal  distribution  after  response  to 
immunosuppressive  treatment,  suggesting  the 
antigen or T cell clearance.
Conclusion: HAA  is  a  life-threatening  condition 
requiring prompt treatment. It  can be considered a 
subset of AA as suggested by pathogenetic immune 
mediated  mechanism  and  by  response  to 
immunosuppressive  therapy.  The  therapeutic 
options are allogeneic HSCT and IST, outcome and 
response rate are similar to those for patients with 
idiopathic acquired aplastic anemia.
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